Company Number: 14470921

Analysis Date: 2025-07-20 12:06 UTC

Financial Health Score: D (Dormant status with minimal activity)

Key Vital Signs:

• Company Status: Active but Dormant (no significant financial transactions reported)
• Cash at bank: £100 consistently over 3 years
• Net Assets / Shareholders Funds: £100 consistently over 3 years
• Account Category: Dormant (exempt from full filing requirements)
• No debts, liabilities, or operational revenues reported

Symptoms Analysis: The company shows the classic signs of a "financial hibernation" state. The balance sheet is static, with minimal cash and no operational assets or liabilities. This indicates there are no active trading activities, revenues, or expenses. The consistency in financial figures over three years suggests the company has not commenced meaningful business operations since incorporation in late 2022. The company remains solvent but essentially inactive.

Diagnosis: 3CR BIOSCIENCE HOLDINGS LIMITED is financially stable in the sense that it is not incurring losses or liabilities, but it shows symptoms of business dormancy—no trading or development activity. The company’s financial health is neutral to weak because it is not generating income or building assets, which are essential for growth and sustainability. This "dormant" condition is akin to a patient in a medically induced coma—stable but not improving or deteriorating.

Prognosis: If the company intends to activate its operations in biotech research and related fields as per SIC codes, it will require infusion of capital, expenditure on R&D, and operational expenses. Without these, the company will remain dormant with a stagnant financial position, limiting its potential growth and value creation. Future financial health depends on the directors’ strategic decisions to commence or accelerate business activities.

Recommendations:

1. Activate operations: Begin business activities aligned with the biotechnology and technical testing fields to generate revenue and justify company existence.
2. Capital infusion: Secure funding to support research, development, and operational costs; the current cash reserves are insufficient for active business.
3. Financial planning: Develop a detailed budget and cash flow forecast to monitor liquidity and avoid future distress symptoms.
4. Regular monitoring: Maintain timely filings and monitor changes in financial position as operations commence.
5. Stakeholder communication: Keep shareholders and potential investors informed about the company’s plans and progress to build confidence.